10/533726 JC14 Rec'd PCT/PTO 04 MAY 2005 NEY DOCKET: 25082-001

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re:

Patent application of:

Rajiv Khanna et al.

Group Art Unit: Not Yet Known

U.S. Serial

No. Not Yet Known

Examiner:

Not Yet Known

Filed:

herewith

International

Application

No. PCT/AU2003/001451

Int'l filing

Date: November 3, 2003

For:

EPSTEIN BARR VIRUS PEPTIDE EPITOPES, POLYEPITOPES AND **DELIVERY SYSTEM THEREFOR**

> Patrick H. Higgins, Esq. Registration No. 39,709 Fox Rothschild, LLP

P.O. Box 5231

Princeton, NJ 08543-5231

Tel: 609-896-7654 Fax: 609-896-1469

Customer No. 29880

Deposit Account: 50-1943

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98,

information relating to the above-identified application is hereby disclosed. Submission

of this statement is not to be construed as an admission that any of the documents submitted herewith are "material" to the examination of this application or the patentability of the invention, as the term "material" is defined in 37 C.F.R. §1.56(b), nor as any admission that the documents submitted herewith even qualify as prior art references with respect to the above-referenced patent application.

In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

To the extent there is any fee required in connection with the receipt, acceptance and/or consideration of this paper and/or any accompanying papers submitted herewith, please charge all such fees to Deposit Account 50-1943.

Respectfully submitted,

Date:

Patrick H. Higgins

Registration No. 39,709 Attorney for Applicants

Fox Rothschild LLP
P.O. Box 5231
Princeton, NJ 08543-5231
609-8967654
Customer No. 29888
e-mail: phiggins@foxrothschild.com

Contact Control of the 2005

List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office FOREIGN PATENT DOCUMENTS Examiner Initial AA 1999/002550 A1 01/1999 WIPO AB 1229043 A1 08/2002 EP AC 2002-255997 09/2002 JAPAN X AD 2001/094944 A2 12/2001 WIPO OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) AE LEEN A et al.: "Differential Immunogenicity of Epstein-Barr Virus Latent-Cycle Proteins for Human CD4+ T-Helper 1 Responses", Journal of Virology, Septembe 2001. p 8649-8659 AF THORLEY-LAWSON D A et al.: "Generation of specific cytotoxic T cells with a fragment of the Epstein-Barr virus-encoded p63/latent membrane protein"; Proceeding of the National Academy of Sciences of the USA (1987), 84(15), 5384-8 AG O'SULLIVAN D ET AL: "Characterization of the specificity of peptide binding to for pp1799-1808 AH MEIJ P et al.: "Identification and prevalence of CD8+ T-cell responses directed again Epstein-Barr virus-encoded latent membrane protein 1 and latent membrane protein 2 International Journal of Cancer, 26 February 2002, 99(1), 93-99 AI KHANNAR et al.: "Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1). Evidence for HLA. A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes"; European Journal of Immunology (1998), 28(2), 451-458 AJ DURAISWAMY J et al.: "Ex Yivo Analysis of T-Cell Responses to Epstein-Barr Virus-Encoded Oncogene Latent Membrane Protein 1 Reveals highly Conversed Epitope Sequences in Virus Isolates form Divers Geographic Regions"; Journal of Virology, July 2003, pp7401-7410							Sheet 1 of 2	
(Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office FOREIGN PATENT DOCUMENTS Examiner Initial Document No. Date Country Translation YES NO AA 1999/002550 A1 01/1999 WIPO AB 1229043 A1 08/2002 EP AC 2002-255997 09/2002 JAPAN X AD 2001/094944 A2 12/2001 WIPO OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) AE LEEN A et al.: "Differential Immunogenicity of Epstein-Barr Virus Latent-Cycle Proteins for Human CD4+ T-Helper 1 Responses"; Journal of Virology, September 2001, p. 8649-8659 AF THORLEY-LAWSON D A et al.: "Generation of specific cytotoxic T cells with a fragment of the Epstein-Barr virus-encoded p63/latent membrane protein"; Proceeding of the National Academy of Sciences of the USA (1987), 84(15), 5384-8 AG O'SULIVAN D ET AL: "Characterization of the specificity of peptide binding to for pp. 18 phalotypes"; The Journal of Immunology, Vol. 145, No. 6, September 15 1990, pp. 1799-1808 AH MEIJ P et al.: "Identification and prevalence of CD8+ T-cell responses directed again: Epstein-Barr virus-encoded latent membrane protein 1 and latent membrane protein 2 International Journal of Cancer, 26 February 2002, 99(1), 93-99 AI KHANNA R et al.: "Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1). Evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes"; European Journal of Immunology (1998), 28(2), 451-458 AJ DURALSWAMY J et al: "Ex Vivo Analysis of T-Cell Responses to Epstein-Barr Virus-Encoded Cnoogene Latent Membrane Protein 1 Reveals highly Conversed Epitope Sequences in Virus Isolates form Divers Geographic Regions"; Journal of Virology, July 2003, pp7401-7410	Form PTO-1449 Modified					Sella ON 6.533726 Not Yet Known		
Patent and Trademark Office POREIGN PATENT DOCUMENTS Examiner Initial AA 1999/002550 A1 01/1999 WIPO AB 1229043 A1 08/2002 EP AC 2002-255997 09/2002 JAPAN X AD 2001/094944 A2 12/2001 WIPO OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) AE LEEN A et al.: "Differential Immunogenicity of Epstein-Barr Virus Latent-Cycle Proteins for Human CD4+ T-Helper 1 Responses"; Journal of Virology, September 2001, p 8649-8659 AF THORLEY-LAWSON D A et al.: "Generation of specific cytotoxic T cells with a fragment of the Epstein-Barr virus-encoded p63/latent membrane protein"; Proceeding of the National Academy of Sciences of the USA (1987), 84(15), 5384-8 AG O'SULLIVAN D ET AL: "Characterization of the specificity of peptide binding to for DR halotypes"; The Journal of Immunology, Vol. 145, No. 6, September 15 1990, pp1799-1808 AH MEIJ P et al.: "Identification and prevalence of CD8+ T-cell responses directed agains Epstein-Barr virus-encoded latent membrane protein 1 and latent membrane protein 2 International Journal of Cancer, 26 February 2002, 99(1), 93-99 AI KHANNA R et al.: "Identification of cytotoxic T cell epitopes within Epstein-Barr virus (BBV) oncogene latent membrane protein 1 (LMP1). Evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes"; European Journal of Immunology (1998), 28(2), 451-458 AJ DURAISWAMY J et al: "Ex Vivo Analysis of T-Cell Responses to Epstein-Barr Virus-Encoded Oncogene Latent Membrane Protein 1 Reveals highly Conversed Epitope Sequences in Virus Isolates form Divers Geographic Regions"; Journal of Virology, July 2003, pp7401-7410					1			
Document No. Date Country Translation YES NO								
Initial AA 1999/002550 A1 01/1999 WIPO AB 1229043 A1 08/2002 EP AC 2002-255997 09/2002 JAPAN X AD 2001/094944 A2 12/2001 WIPO OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) AE LEEN A et al.: "Differential Immunogenicity of Epstein-Barr Virus Latent-Cycle Proteins for Human CD4+ T-Helper 1 Responses"; Journal of Virology, Septembe 2001, p 8649-8659 AF THORLEY-LAWSON D A et al.: "Generation of specific cytotoxic T cells with a fragment of the Epstein-Barr virus-encoded p63/latent membrane protein"; Proceeding of the National Academy of Sciences of the USA (1987), 84(15), 5384-8 AG O'SULLIVAN D ET AL: "Characterization of the specificity of peptide binding to for DR halotypes"; The Journal of Immunology, Vol. 145, No. 6, September 15 1990, pp1799-1808 AH MEIJ P et al.: "Identification and prevalence of CD8+ T-cell responses directed again: Epstein-Barr virus-encoded latent membrane protein 1 and latent membrane protein 2 International Journal of Cancer, 26 February 2002, 99(1), 93-99 AI KHANNA R et al.: "Identification of cytotoxic T cell epitopes within Epstein-Barr virus (BBV) oncogene latent membrane protein 1 (LMP1). Evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes"; European Journal of Immunology (1998), 28(2), 451-458 AJ DURAISWAMY J et al: "Ex Vivo Analysis of T-Cell Responses to Epstein-Barr Virus-Encoded Oncogene Latent Membrane Protein 1 Reveals highly Conversed Epitope Sequences in Virus Isolates form Divers Geographic Regions"; Journal of Virology, July 2003, pp7401-7410	FOREIGN I	PATEI	NT DOCUMENTS					
No	Examiner	yaminer Document No. Da			Country	Translation		
AB 1229043 A1 08/2002 EP AC 2002-255997 09/2002 JAPAN X AD 2001/094944 A2 12/2001 WIPO OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) AE LEEN A et al.: "Differential Immunogenicity of Epstein-Barr Virus Latent-Cycle Proteins for Human CD4+ T-Helper 1 Responses"; Journal of Virology, Septembe 2001. p 8649-8659 AF THORLEY-LAWSON D A et al.: "Generation of specific cytotoxic T cells with a fragment of the Epstein-Barr virus-encoded p63/latent membrane protein"; Proceeding of the National Academy of Sciences of the USA (1987), 84(15), 5384-8 AG O'SULLIVAN D ET AL: "Characterization of the specificity of peptide binding to for DR halotypes"; The Journal of Immunology, Vol. 145, No. 6, September 15 1990, pp1799-1808 AH MEIJ P et al.: "Identification and prevalence of CD8+ T-cell responses directed again: Epstein-Barr virus-encoded latent membrane protein 1 and latent membrane protein 2" International Journal of Cancer, 26 February 2002, 99(1), 93-99 AI KHANNA R et al.: "Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1). Evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes"; European Journal of Immunology (1998), 28(2), 451-458 AJ DURAISWAMY J et al: "Ex Vivo Analysis of T-Cell Responses to Epstein-Barr Virus-Encoded Oncogene Latent Membrane Protein 1 Reveals highly Conversed Epitope Sequences in Virus Isolates form Divers Geographic Regions"; Journal of Virology, July 2003, pp7401-7410						YES	NO	
AC 2002-255997 09/2002 JAPAN X AD 2001/094944 A2 12/2001 WIPO OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) AE LEEN A et al.: "Differential Immunogenicity of Epstein-Barr Virus Latent-Cycle Proteins for Human CD4+ T-Helper 1 Responses"; Journal of Virology, September 2001, p 8649-8659 AF THORLEY-LAWSON D A et al.: "Generation of specific cytotoxic T cells with a fragment of the Epstein-Barr virus-encoded p63/latent membrane protein"; Proceeding of the National Academy of Sciences of the USA (1987), 84(15), 5384-8 AG O'SULLIVAN D ET AL: "Characterization of the specificity of peptide binding to for DR halotypes"; The Journal of Immunology, Vol. 145, No. 6, September 15 1990, pp1799-1808 AH MEIJ P et al.: "Identification and prevalence of CD8+ T-cell responses directed again: Epstein-Barr virus-encoded latent membrane protein 1 and latent membrane protein 2 International Journal of Cancer, 26 February 2002, 99(1), 93-99 AI KHANNA R et al.: "Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1). Evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes"; European Journal of Immunology (1998), 28(2), 451-458 AJ DURAISWAMY J et al: "Ex Vivo Analysis of T-Cell Responses to Epstein-Barr Virus-Encoded Oncogene Latent Membrane Protein 1 Reveals highly Conversed Epitope Sequences in Virus Isolates form Divers Geographic Regions"; Journal of Virology, July 2003, pp7401-7410		AA	1999/002550 A1	01/1999	WIPO			
AD 2001/094944 A2 12/2001 WIPO OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) AE LEEN A et al.: "Differential Immunogenicity of Epstein-Barr Virus Latent-Cycle Proteins for Human CD4+ T-Helper 1 Responses"; Journal of Virology, September 2001, p 8649-8659 AF THORLEY-LAWSON D A et al.: "Generation of specific cytotoxic T cells with a fragment of the Epstein-Barr virus-encoded p63/latent membrane protein"; Proceeding of the National Academy of Sciences of the USA (1987), 84(15), 5384-8 AG O'SULLIVAN D ET AL: "Characterization of the specificity of peptide binding to for DR halotypes"; The Journal of Immunology, Vol. 145, No. 6, September 15 1990, pp1799-1808 AH MEIJ P et al.: "Identification and prevalence of CD8+ T-cell responses directed against Epstein-Barr virus-encoded latent membrane protein 1 and latent membrane protein 2' International Journal of Cancer, 26 February 2002, 99(1), 93-99 AI KHANNA R et al.: "Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1). Evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes"; European Journal of Immunology (1998), 28(2), 451-458 AJ DURAISWAMY J et al: "Ex Vivo Analysis of T-Cell Responses to Epstein-Barr Virus-Encoded Oncogene Latent Membrane Protein 1 Reveals highly Conversed Epitope Sequences in Virus Isolates form Divers Geographic Regions"; Journal of Virology, July 2003, pp7401-7410		AB	1229043 A1	08/2002	EP			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) AE LEEN A et al.: "Differential Immunogenicity of Epstein-Barr Virus Latent-Cycle Proteins for Human CD4+ T-Helper 1 Responses"; Journal of Virology, September 2001. p 8649-8659 AF THORLEY-LAWSON D A et al.: "Generation of specific cytotoxic T cells with a fragment of the Epstein-Barr virus-encoded p63/latent membrane protein"; Proceeding of the National Academy of Sciences of the USA (1987), 84(15), 5384-8 AG O'SULLIVAN D ET AL: "Characterization of the specificity of peptide binding to for DR halotypes"; The Journal of Immunology, Vol. 145, No. 6, September 15 1990, pp1799-1808 AH MEIJ P et al.: "Identification and prevalence of CD8+ T-cell responses directed against Epstein-Barr virus-encoded latent membrane protein 1 and latent membrane protein 2 International Journal of Cancer, 26 February 2002, 99(1), 93-99 AI KHANNA R et al.: "Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1). Evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes"; European Journal of Immunology (1998), 28(2), 451-458 AJ DURAISWAMY J et al.: "Ex Vivo Analysis of T-Cell Responses to Epstein-Barr Virus-Encoded Oncogene Latent Membrane Protein 1 Reveals highly Conversed Epitope Sequences in Virus Isolates form Divers Geographic Regions"; Journal of Virology, July 2003, pp7401-7410		AC	2002-255997	09/2002	JAPAN	X		
AE LEEN A et al.: "Differential Immunogenicity of Epstein-Barr Virus Latent-Cycle Proteins for Human CD4+ T-Helper 1 Responses"; Journal of Virology, September 2001. p 8649-8659 AF THORLEY-LAWSON D A et al.: "Generation of specific cytotoxic T cells with a fragment of the Epstein-Barr virus-encoded p63/latent membrane protein"; Proceeding of the National Academy of Sciences of the USA (1987), 84(15), 5384-8 AG O'SULLIVAN D ET AL: "Characterization of the specificity of peptide binding to for DR halotypes"; The Journal of Immunology, Vol. 145, No. 6, September 15 1990, pp1799-1808 AH MEIJ P et al.: "Identification and prevalence of CD8+ T-cell responses directed against Epstein-Barr virus-encoded latent membrane protein 1 and latent membrane protein 2' International Journal of Cancer, 26 February 2002, 99(1), 93-99 AI KHANNA R et al.: "Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1). Evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes"; European Journal of Immunology (1998), 28(2), 451-458 AJ DURAISWAMY J et al.: "Ex Vivo Analysis of T-Cell Responses to Epstein-Barr Virus-Encoded Oncogene Latent Membrane Protein 1 Reveals highly Conversed Epitope Sequences in Virus Isolates form Divers Geographic Regions"; Journal of Virology, July 2003, pp7401-7410		AD	2001/094944 A2	12/2001	WIPO			
AE LEEN A et al.: "Differential Immunogenicity of Epstein-Barr Virus Latent-Cycle Proteins for Human CD4+ T-Helper 1 Responses"; Journal of Virology, September 2001. p. 8649-8659 AF THORLEY-LAWSON D A et al.: "Generation of specific cytotoxic T cells with a fragment of the Epstein-Barr virus-encoded p63/latent membrane protein"; Proceeding of the National Academy of Sciences of the USA (1987), 84(15), 5384-8 AG O'SULLIVAN D ET AL: "Characterization of the specificity of peptide binding to for DR halotypes"; The Journal of Immunology, Vol. 145, No. 6, September 15 1990, pp1799-1808 AH MEIJ P et al.: "Identification and prevalence of CD8+ T-cell responses directed against Epstein-Barr virus-encoded latent membrane protein 1 and latent membrane protein 2' International Journal of Cancer, 26 February 2002, 99(1), 93-99 AI KHANNA R et al.: "Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1). Evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes"; European Journal of Immunology (1998), 28(2), 451-458 AJ DURAISWAMY J et al: "Ex Vivo Analysis of T-Cell Responses to Epstein-Barr Virus-Encoded Oncogene Latent Membrane Protein 1 Reveals highly Conversed Epitope Sequences in Virus Isolates form Divers Geographic Regions"; Journal of Virology, July 2003, pp7401-7410	OTHER DO	CUM	ENTS (Including A	uthor, Title, [Date, Pertinent Page	s, Etc.)		
fragment of the Epstein-Barr virus-encoded p63/latent membrane protein"; Proceeding of the National Academy of Sciences of the USA (1987), 84(15), 5384-8 AG O'SULLIVAN D ET AL: "Characterization of the specificity of peptide binding to for DR halotypes"; The Journal of Immunology, Vol. 145, No. 6, September 15 1990, pp1799-1808 AH MEIJ P et al.: "Identification and prevalence of CD8+ T-cell responses directed against Epstein-Barr virus-encoded latent membrane protein 1 and latent membrane protein 2' International Journal of Cancer, 26 February 2002, 99(1), 93-99 AI KHANNA R et al.: "Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1). Evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes"; European Journal of Immunology (1998), 28(2), 451-458 AJ DURAISWAMY J et al: "Ex Vivo Analysis of T-Cell Responses to Epstein-Barr Virus-Encoded Oncogene Latent Membrane Protein 1 Reveals highly Conversed Epitope Sequences in Virus Isolates form Divers Geographic Regions"; Journal of Virology, July 2003, pp7401-7410	<u>. </u>	AE	Proteins for Human CD4+ T-Helper 1 Responses"; Journal of Virology, September					
DR halotypes"; The Journal of Immunology, Vol. 145, No. 6, September 15 1990, pp1799-1808 AH MEIJ P et al.: "Identification and prevalence of CD8+ T-cell responses directed against Epstein-Barr virus-encoded latent membrane protein 1 and latent membrane protein 2' International Journal of Cancer, 26 February 2002, 99(1), 93-99 AI KHANNA R et al.: "Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1). Evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes"; European Journal of Immunology (1998), 28(2), 451-458 AJ DURAISWAMY J et al: "Ex Vivo Analysis of T-Cell Responses to Epstein-Barr Virus-Encoded Oncogene Latent Membrane Protein 1 Reveals highly Conversed Epitope Sequences in Virus Isolates form Divers Geographic Regions"; Journal of Virology, July 2003, pp7401-7410		AF	fragment of the Epstein-Barr virus-encoded p63/latent membrane protein"; Proceedings					
Epstein-Barr virus-encoded latent membrane protein 1 and latent membrane protein 2' International Journal of Cancer, 26 February 2002, 99(1), 93-99 Al KHANNA R et al.: "Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1). Evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes"; European Journal of Immunology (1998), 28(2), 451-458 AJ DURAISWAMY J et al: "Ex Vivo Analysis of T-Cell Responses to Epstein-Barr Virus-Encoded Oncogene Latent Membrane Protein 1 Reveals highly Conversed Epitope Sequences in Virus Isolates form Divers Geographic Regions"; Journal of Virology, July 2003, pp7401-7410	<u>.</u>	AG						
virus (EBV) oncogene latent membrane protein 1 (LMP1). Evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes"; European Journal of Immunology (1998), 28(2), 451-458 AJ DURAISWAMY J et al: "Ex Vivo Analysis of T-Cell Responses to Epstein-Barr Virus-Encoded Oncogene Latent Membrane Protein 1 Reveals highly Conversed Epitope Sequences in Virus Isolates form Divers Geographic Regions"; Journal of Virology, July 2003, pp7401-7410		АН	MEIJ P et al.: "Identification and prevalence of CD8+ T-cell responses directed against Epstein-Barr virus-encoded latent membrane protein 1 and latent membrane protein 2"; International Journal of Cancer, 26 February 2002, 99(1), 93-99					
Virus-Encoded Oncogene Latent Membrane Protein 1 Reveals highly Conversed Epitope Sequences in Virus Isolates form Divers Geographic Regions"; Journal of Virology, July 2003, pp7401-7410		AI	virus (EBV) oncogene latent membrane protein 1 (LMP1). Evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes"; European Journal of Immunology (1998), 28(2), 451-458					
		AJ	Virus-Encoded Onc Epitope Sequences	ogene Latent N in Virus Isolate	Membrane Protein 1 Re es form Divers Geograp	veals highl	y Conversed	
EXAMINER DATE CONSIDERED	EXAMINER			DATE C	DATE CONSIDERED			



Sheet 2 of 2

Form PTO-144	9 Modified	Client Matter No. FAK-001	Selially 533726 Not Yet Known			
List of Patent and (Use several shee	Publications Cited by Applicates if necessary)		Applicant Rajiv Khanna et al.			
U.S. Department Patent and Trade	mark Office	Filing Date herewith	Group Not Yet Known			
OTHER DOCUM	ENTS (Including Author, Tit					
AK	DURAISWAMY J et al: "Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma"; Blood, 15 April 2003, 101(8), 3150-3156					
AL	KHANNA R et al.: "Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease"; Proceedings of the National Academy of Sciences of the USA (1999), 96(18), 10391-10396					
AM	AM GENPEPT accession no AAA53227; SAMPLE J et al.: "Epstein-Barr virus types 1 and 2 have nearly identical LMP-1 transforming genes"; (& PUBMED 7931160)					
EXAMINER		E CONSIDERED	ONSIDERED			